Ignite Creation Date:
2025-12-24 @ 1:48 PM
Ignite Modification Date:
2025-12-29 @ 12:21 PM
Study NCT ID:
NCT01213095
Status:
COMPLETED
Last Update Posted:
2016-04-11
First Post:
2010-09-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
Sponsor:
Dong-A University Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CISL-MZL-10-4(ML25403)
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None